Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia
- 1 January 1998
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 17 (1) , 23-28
- https://doi.org/10.1097/00006454-199801000-00006
Abstract
Streptococcus pneumoniae is a major cause of morbidity and mortality in young children in the developing world. The recent development of pneumococcal polysaccharide/protein conjugate vaccines may make possible prevention of this infection. However, little is known about the epidemiology of invasive pneumococcal disease in children in the developing world. To determine the incidence and epidemiologic features of invasive pneumococcal disease in children resident in a semiurban area of The Gambia. The study was part of a large trial of an Haemophilus influenzae type b vaccine that recruited 42 848 children at the age of 2 months during the period March, 1993, to October, 1995. Follow-up of study children continued until December 31, 1995; therefore the first children to enter the trial were followed for 2.5 years and the last for just a few months. During the period of surveillance, 2256 children were investigated for possible invasive pneumococcal disease when they presented to a hospital or health center. We detected 110 cases of pneumococcal disease. Pneumonia was the most common form of invasive pneumococcal disease observed (75.5% of patients). The incidence of pneumococcal disease was 224[95% confidence interval (CI) 171, 277] per 100 000 child years among children ages 2 to 11 months, 139 (95% CI 93, 184) per 100 000 among children ages 12 to 23 months and 82 (95% CI 21, 143) per 100,000 among children ages 24 to 35 months. Pneumococci of serogroups 14, 6, 5, 23, 19, 46 and 2 were isolated most frequently. Susceptibility to pneumococcal disease was not increased significantly among Haemophilus influenzae type b-vaccinated children. The pneumococcus is a major cause of bacterial infection in The Gambia. A proposed nine-valent pneumococcal conjugate vaccine for developing countries containing conjugates of serogroups 1, 4, 5, 6, 9, 14, 18, 19 and 23 would cover 74%% of cases of invasive pneumococcal disease in children resident in the Western Region of The Gambia.Keywords
This publication has 27 references indexed in Scilit:
- Pneumococcal disease among children in a rural area of West AfricaThe Pediatric Infectious Disease Journal, 1996
- The etiology of pneumonia in malnourished and well-nourished Gambian childrenThe Pediatric Infectious Disease Journal, 1994
- Antibody response to pneumococcal capsular polysaccharide vaccine in African childrenThe Pediatric Infectious Disease Journal, 1991
- Antibodies to pneumococcal polysaccharides in pneumonia and response to pneumococcal vaccination in young children in Papua New GuineaClinical and Experimental Immunology, 1991
- Etiology of acute lower respiratory tract infections in Gambian childrenThe Pediatric Infectious Disease Journal, 1991
- Etiology of acute lower respiratory tract infections in Gambian childrenThe Pediatric Infectious Disease Journal, 1991
- Etiology of severe pneumonia in children in developing countriesThe Pediatric Infectious Disease Journal, 1986
- Acute Respiratory Infections Are the Leading Cause of Death in Children in Developing CountriesThe American Journal of Tropical Medicine and Hygiene, 1986
- Vaccination Against Streptococcus pneumoniae in Childhood: Lack of Demonstrable Benefit in Young Australian ChildrenThe Journal of Infectious Diseases, 1984
- Antibody Response to Pneumococcal Vaccination in Children Younger than Five Years of AgeThe Journal of Infectious Diseases, 1983